Mechanical release of homogenous proteins from supramolecular gels.

Autor: Bianco S; Department of Chemistry, University of Glasgow, Glasgow, UK., Hasan M; Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK., Ahmad A; Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.; Department of Chemistry, University of Warwick, Coventry, UK., Richards SJ; Department of Chemistry, University of Warwick, Coventry, UK.; Department of Chemistry, University of Manchester, Manchester, UK., Dietrich B; Department of Chemistry, University of Glasgow, Glasgow, UK., Wallace M; School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, UK., Tang Q; Department of Chemistry, University of Warwick, Coventry, UK., Smith AJ; Diamond Light Source Ltd, Diamond House, Harwell Science and Innovation Campus, Didcot, UK., Gibson MI; Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK. matt.gibson@manchester.ac.uk.; Department of Chemistry, University of Warwick, Coventry, UK. matt.gibson@manchester.ac.uk.; Department of Chemistry, University of Manchester, Manchester, UK. matt.gibson@manchester.ac.uk.; Manchester Institute of Biotechnology, University of Manchester, Manchester, UK. matt.gibson@manchester.ac.uk., Adams DJ; Department of Chemistry, University of Glasgow, Glasgow, UK. dave.adams@glasgow.ac.uk.
Jazyk: angličtina
Zdroj: Nature [Nature] 2024 Jul; Vol. 631 (8021), pp. 544-548. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1038/s41586-024-07580-0
Abstrakt: A long-standing challenge is how to formulate proteins and vaccines to retain function during storage and transport and to remove the burdens of cold-chain management. Any solution must be practical to use, with the protein being released or applied using clinically relevant triggers. Advanced biologic therapies are distributed cold, using substantial energy, limiting equitable distribution in low-resource countries and placing responsibility on the user for correct storage and handling. Cold-chain management is the best solution at present for protein transport but requires substantial infrastructure and energy. For example, in research laboratories, a single freezer at -80 °C consumes as much energy per day as a small household 1 . Of biological (protein or cell) therapies and all vaccines, 75% require cold-chain management; the cost of cold-chain management in clinical trials has increased by about 20% since 2015, reflecting this complexity. Bespoke formulations and excipients are now required, with trehalose 2 , sucrose or polymers 3 widely used, which stabilize proteins by replacing surface water molecules and thereby make denaturation thermodynamically less likely; this has enabled both freeze-dried proteins and frozen proteins. For example, the human papilloma virus vaccine requires aluminium salt adjuvants to function, but these render it unstable against freeze-thaw 4 , leading to a very complex and expensive supply chain. Other ideas involve ensilication 5 and chemical modification of proteins 6 . In short, protein stabilization is a challenge with no universal solution 7,8 . Here we designed a stiff hydrogel that stabilizes proteins against thermal denaturation even at 50 °C, and that can, unlike present technologies, deliver pure, excipient-free protein by mechanically releasing it from a syringe. Macromolecules can be loaded at up to 10 wt% without affecting the mechanism of release. This unique stabilization and excipient-free release synergy offers a practical, scalable and versatile solution to enable the low-cost, cold-chain-free and equitable delivery of therapies worldwide.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: